In vitro activity of moxifloxacin against 179 strains of anaerobic bacteria found in pulmonary infections

Anaerobe

Volumn 6, Issue 4, 2000, Pages 227-231

  Wexler, Hannah M ^b,c   Molitoris, Eric ^c   Molitoris, Denise ^b   Finegold, Sydney M ^a,b,c  

^a VisionCare Associates PC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEROIDES FRAGILIS; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; FUSOBACTERIUM; LUNG INFECTION; NONHUMAN; PEPTOSTREPTOCOCCUS; PREVOTELLA; PRIORITY JOURNAL;

EID: 0033864090     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1006/anae.2000.0348     Document Type: Article

References (18)

1. Civen R., Jousimies-Somer H., Marina M., Borenstein L., Shah H., Finegold S. M. A retrospective review of cases of anaerobic empyema and update of bacteriology. Clin Infect Dis. 20:1995;S224-S229.
2. Rasmussen B. A., Bush K., Tally F. P. Antimicrobial resistance in anaerobes. Clin Infect Dis. 24:1997;S110-S120.
3. Salyers A. A., Shoemaker N. B. Resistance gene transfer in anaerobes: new insights, new problems. Clin Infect Dis. 23:1996;S36-S43.
4. Roberts M. C. Distribution of tetracycline and macrolide-lincosamide-streptogramin B resistance genes in anaerobic bacteria. Clin Infect Dis. 20:1995;S367-S369.
5. Hecht D. W., Wexler H. M. In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis. 23:1996;S2-S8.
6. Balfour J. A., Wiseman L. R. Moxifloxacin. Drugs. 57:1999;363-373.
7. Al-Nawas B., Shah P. M. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 41:1998;655-658.
8. Alcala L., Cercenado E., Garcia-Garrote F., Bouza E. In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant Gram-positive clinical isolates. Diagn Microbiol Infect Dis. 33:1999;27-31.
9. Biedenbach D. J., Barrett M. S., Croco M. A., Jones R. N. BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens. Diagn Microbiol Infect Dis. 32:1998;45-50.
10. Summanen P., Baron E. J., Citron D., Strong C., Wexler H. M., Finegold S. M. Wadsworth Anaerobic Bacteriology Manual. 1993;Star Publishing Company, Belmont.
11. National Committee for Clinical Laboratory Standards, 1997, Methods for antimicrobial susceptibility testing of anaerobic bacteria, NCCLS, Wayne, PA.
12. Wexler H. M., Finegold S. M. Current susceptibility patterns of anaerobic bacteria. Yonsei Med J. 39:1998;495-501.
13. Aldridge K. E., Ashcraft D. S. Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother. 41:1997;709-711.
14. Betriu C., Gomez M., Palau M. L., Sanchez A., Picazo J. J. Activities of New Antimicrobial Agents (Trovafloxacin, Moxifloxacin, Sanfetrinem, and Quinupristin-Dalfopristin) againstBacteroides fragilis Group: Comparison with the Activities of 14 Other Agents. Antimicrob Agents Chemother. 43:1999;1999-2322.
15. Edlund C., Sabouri S., Nord C. E. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 17:1998;193-195.
16. Goldstein E. J., Citron D. M., Hudspeth M., Gerardo S. H., Merriam C. V. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother. 41:1997;1552-1557.
17. MacGowan A. P., Bowker K. E., Holt H. A., Wootton M., Reeves D. S. Bay 12-8039, a new 8-methoxy-quinolone: comparative in vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother. 40:1997;503-509.
18. Souli M., Wennersten C. B., Eliopoulos G. M. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents. 10:1998;23-30.